National Institute of Blood Disease & Bone Marrow Transplantation (NIBD)

What National Institute of Blood Disease & Bone Marrow Transplantation (NIBD) does

The National Institute of Blood Disease & Bone Marrow Transplantation (NIBD) is a private Pakistani specialty hospital network founded in 1996 by Prof. Dr. Tahir Sultan Shamsi (late), headquartered in Karachi, Sindh, and operating across four cities: Karachi, Lahore, Sukkur, and Hyderabad. The institution is positioned as Pakistan's pioneer in bone marrow transplantation, with cumulative volumes exceeding 1,300 BMT procedures and approximately 10,000 new blood disease and cancer patients treated annually, supported by 263 total employees including 18+ specialist physicians in haematology, oncology, and transplant medicine.

NIBD's service portfolio spans core clinical offerings (autologous, allogeneic, and haploidentical bone marrow transplantation; haematology and oncology; CAR-T cell therapy and immunotherapy; targeted therapies), advanced diagnostics (molecular diagnostics, cytogenetics, flow cytometry, clinical genomics, 3D hematology testing, tele morphology), and supporting functions (blood bank, pharmacy, specialized nursing, research, Institutional Review Board). The network also operates postgraduate fellowship programs in clinical and lab haematology and BMT, and publishes the National Journal of Health Sciences.

The business model is sales-led and referral-driven, with patients acquired through medical professional referrals, emergency services (24/7 hotline), and institutional partnerships across Pakistan. Revenue streams include patient healthcare services (consultations, diagnostics, chemotherapy, transplantation, ongoing care), educational and fellowship programs, and journal publication licensing. Pricing is described as welfare-oriented and not publicly disclosed, set through individual patient assessment, insurance coverage, or government health schemes. Ownership is private with no disclosed parent company, external investors, or public listing.

Name

National Institute of Blood Disease & Bone Marrow Transplantation (NIBD)

Legal name

National Institute of Blood Disease & Bone Marrow Transplantation

Website

https://nibd.edu.pk

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

NIBD is Pakistan's pioneer private specialty hospital network for blood diseases and bone marrow transplantation, operating four campuses (Karachi, Lahore, Sukkur, Hyderabad) and treating 10,000 new patients annually with 1,300+ cumulative BMTs performed.

Ownership category

akta.pro rank

Product category

Specialty Hematology and Oncology Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Haematology oncology services
• Bone marrow transplantation
• Blood cancer treatment
• Diagnostic laboratory services
• Haematology fellowship training

Headquarters

HQ city

Karachi

HQ country

Pakistan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Patient Healthcare Services: Revenue generated from comprehensive diagnostic, treatment, and transplant services for patients with blood diseases, blood cancers, and other conditions. Services include consultations, diagnostics, chemotherapy, bone marrow transplantation, and ongoing patient care.
2. Educational & Training Programs: Postgraduate training, fellowship programs, and professional development courses for medical professionals in haematology, oncology, bone marrow transplantation, and related fields.
3. National Journal of Health Sciences: Publication revenue from the peer-reviewed journal serving as a platform for healthcare professionals to disseminate research in health sciences.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

NIBD operates a multi-campus teaching hospital network delivering specialised clinical care, diagnosis, and bone marrow transplantation for blood diseases, blood cancers, and related disorders. Core offerings span bone marrow transplantation, haematology and oncology treatment, advanced diagnostic laboratory services, a 24/7 blood bank, oncology pharmacy, dedicated nursing, and postgraduate fellowship training. The network serves patients across four Pakistani cities (Karachi, Lahore, Sukkur, Hyderabad) and supports research and a peer-reviewed health sciences journal.

Product overview

NIBD operates as a multi-campus teaching hospital network offering a comprehensive suite of medical services centred on haematology, oncology, and bone marrow transplantation. The core portfolio spans clinical services (Bone Marrow Transplantation, Haematology & Oncology), diagnostic services (Laboratory Services, Blood Bank), and supporting services (Pharmacy, Nursing, Research, Institutional Review Board). Educational offerings include Post Graduate Training & Post Fellowship programs, and the institution publishes the National Journal of Health Sciences. The network operates across four cities in Pakistan (Karachi, Lahore, Sukkur, Hyderabad) and reports treating approximately 10,000 new patients annually with over 1,300 bone marrow transplants performed.

Differentiator

Problem solved

Functional benefit

Brands

• National Journal of Health Sciences (NJHS): Official peer-reviewed publication of NIBD, serving as a platform for healthcare professionals to disseminate research in health sciences. Open-access, double-anonymized journal with ISSN 2519-7053 (Print) and ISSN 2519-7878 (Online).

Products and services

• Bone Marrow Transplantation Comprehensive bone marrow transplant services including autologous, allogeneic, and haploidentical transplants for adult and paediatric patients treating blood cancers, bone marrow failure syndromes, and hemoglobinopathies.
• Haematology & Oncology Comprehensive care for patients with blood disorders and cancers, covering malignant disorders (leukaemia, lymphoma, myeloma), benign disorders, solid tumours, haemoglobinopathies, myeloproliferative neoplasms, bone marrow failure disorders, and haemostasis and coagulation disorders.
• Laboratory Services Advanced diagnostic laboratory services including haematology, clinical chemistry, molecular diagnostics, immunohematology, cytogenetics, flow cytometry, mass spectrometry, bone marrow evaluation, 3D haematology testing, tele morphology, and clinical genomics.
• Blood Bank Comprehensive blood bank services including blood collection, processing, component preparation, infectious disease screening, blood typing, storage, transfusion services, and specialised blood products like irradiated components and HLA-matched platelets.
• Pharmacy Oncology and haematology focused pharmacy providing medication management, clinical pharmacy services, patient education, specialised oncology and haematology services, compounding services, and research involvement.
• Nursing Specialised nursing services in haematology and oncology including inpatient care, outpatient clinics, day care centre, ICU, palliative care, and bone marrow transplant nursing with specialised training programs.
• Research R&D department advancing haematology and oncology through basic and translational research, clinical studies, epidemiology, innovative therapies (targeted therapies, immunotherapy, CAR-T cell therapy), and collaborative scientific initiatives.
• Institutional Review Board (IRB) Ethical oversight committee ensuring the ethical and responsible conduct of research involving human subjects, protecting rights and welfare of research participants.
• National Journal of Health Sciences Peer-reviewed open-access journal publishing scholarly articles in health sciences, serving as the official publication of NIBD with double-blind peer review process.

Quantifiable outcome

• 1300+ bone marrow transplants performed
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• Leading Academic InstitutionscoreStrategic or Co-development PartnerCollaborative research partnerships with national and international academic institutions for advancing haematology and oncology knowledge, sharing data, resources, and expertise through consortium memberships.
• Biotechnology & Pharmaceutical CompaniescoreStrategic or Co-development PartnerIndustry partnerships for developing and testing new therapies, clinical trials collaboration, and accessing innovative treatment modalities and drug development.
• International Healthcare OrganisationscoreStrategic or Co-development PartnerParticipation in international consortia for knowledge sharing, collaborative research projects, and adoption of global best practices in haematology and oncology treatment.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• King Faisal Specialist Hospital & Research Centre: Saudi Arabia's leading tertiary specialty hospital and BMT center, a regional Gulf referral hub. Comparable to NIBD as a high-acuity specialty institution with BMT and CAR-T capability, but operates at top tier scale with government backing.
• Apollo Hospitals: India's largest private hospital network with established hematology, BMT, and CAR-T programs. Comparable to NIBD as a private specialty provider offering advanced hematology care, but at far larger scale and with deeper capital base — a likely long-term competitor for regional cross-border patients.
• Max Healthcare (BLK-Max, Max Saket): Indian private hospital chain with active hematology, BMT, and CAR-T programs. Comparable to NIBD as a private specialty hematology/oncology provider in South Asia, with a more commercially-driven (less welfare-oriented) model.
• Aga Khan University Hospital: Tertiary care teaching hospital in Karachi with multiple specialty programs including hematology/oncology. Comparable to NIBD as a private Pakistani teaching hospital but broader in scope (general multispecialty) and serves as a peer referral source for complex hematology cases.

Direct peers

• Tata Memorial Hospital: India's premier public specialty cancer hospital in Mumbai, a regional referral center for hematologic malignancies and BMT. Directly comparable to NIBD as a high-volume specialty oncology/BMT institution, but operates at meaningfully larger scale and serves as the regional standard-setter.
• Indus Hospital & Health Network: Welfare-oriented, free-of-charge hospital network in Pakistan with a flagship campus in Karachi and multiple satellite sites. Comparable to NIBD in its welfare-oriented operating model and multi-city network footprint, though it is broader in specialty scope.
• Christian Medical College (CMC) Vellore: Tertiary teaching hospital in India with a strong hematology and BMT program. Comparable to NIBD as a mission/academic specialty institution with fellowship programs and hematology research, though broader in overall scope.
• Shaukat Khanum Memorial Cancer Hospital: Pakistan's flagship oncology specialty hospital network, founded in Lahore with a second facility in Peshawar. Directly comparable to NIBD as a privately operated, multi-city Pakistani cancer hospital offering chemotherapy, BMT-adjacent services, and cancer diagnostics — though NIBD is more hematology/BMT-focused while SKM is more solid-tumor-led.

Regional players

• PGIMER (Postgraduate Institute of Medical Education and Research): Public tertiary care and teaching hospital in Chandigarh, India, with a large hematology and BMT program. Comparable to NIBD as a teaching/research hematology institution, but operates as a public-sector peer rather than a private welfare institution.

Emerging players

• The Aga Khan Health Services: Operates healthcare services across Pakistan and East Africa, including secondary and tertiary facilities. Comparable to NIBD as a multi-country, mission-driven hospital operator in overlapping geographies, and a potential partner acquirer for BMT/hematology expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/nibdpk
• YouTubeyoutube.com/channel/nibdpk
• Facebookfacebook.com/nibdpk
• Instagraminstagram.com/nibdpk
• LinkedInlinkedin.com/company/nibd

Revenue estimate

Valuation estimate

Number of profiles

Profiles28 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Institute of Blood Disease & Bone Marrow Transplantation (NIBD)